The Latest Cardiac and Vascular News
– ACCESS 2 is a randomized clinical trial evaluating Sirogen for improving hemodialysis AV Fistula outcomes – CRESSKILL, N.J., Aug. 29, 2022 /PRNewswire/ — Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, […]
– Proceeds to fund ACCESS 2 – a randomized clinical trial evaluating Sirogen™ for improving hemodialysis AV Fistula outcomes in high-risk patients – CRESSKILL, N.J., March 29, 2022 /PRNewswire/ — Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access […]
– Sirogen™ Shows Encouraging AV Fistula Outcomes in Elderly End-Stage Renal Disease Patients – CRESSKILL, N.J., Nov. 4, 2021 /PRNewswire/ — Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical […]
– Sirogen™ Shows Encouraging AV Fistula Outcomes in Elderly End-Stage Renal Disease Patients – CRESSKILL, N.J.–(BUSINESS WIRE)–Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood […]
– Company funded through 2020. Topline Phase 3 results for Sirogen expected to be announced in Q2 2020 – CRESSKILL, N.J, January 28, 2020 – Vascular Therapies, a clinical-stage biopharma company focused on improving vascular access outcomes in patients with […]
CRESSKILL, N.J., Sept. 9, 2019 /PRNewswire/ — Vascular Therapies, a clinical stage biotechnology company, is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local, perivascular drug delivery focused on improving vascular access outcomes in patients with kidney disease. Daniel G. Clair, MD, vascular surgeon […]
CRESSKILL, N.J., Jan. 9, 2019 /PRNewswire/ — Vascular Therapies, a biotechnology company focused on improving outcomes for patients with advanced kidney disease, today announced the appointment of John McDermott as the Company’s Chief Executive Officer. Bob Croce, Chairman of the Board of Directors of Vascular […]
CRESSKILL, N.J., Nov. 9, 2017 /PRNewswire/ — An innovative, investigational treatment approach is showing the potential to address an important, unresolved problem encountered by patients with kidney failure on dialysis. At the recent annual meeting of the American Society of […]
